Psychiatr Danub 2011 Sep;23 Suppl 1:S15-7
Université Catholique de Louvain, Clinic of Mont-Godinne, 5530 Yvoir, Belgium.
|PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
Encephale 2002 Nov-Dec;28(6 Pt 1):542-51
UHP, Secteur 3, Unité de Recherche Clinique, 5, rue du Docteur Delafontaine, 93200 Saint-Denis.
The strategy in the choice of antipsychotic agent must take into account the hepatic tolerance according to non-negligible incidence of liver disorders among psychiatric population (presence of risk factors like alcoholism, drugs of abuse intake, polymedication including potentially hepatotoxic drugs.). More than 1 000 drugs have been listed as being responsible of hepatic side effects; 16% of these agents were neuropsychiatric drugs. Read More
Encephale 2005 Mar-Apr;31(2):235-46
Service de Psychiatrie, CHU, Clermont-Ferrand, France.
Unlabelled: Schizophrenia is a disease affecting the young adults and amounts to approximately 300,000 people in France. The French public psychiatric sector takes care of approximately 150,000 adults schizophrenics: 50% benefit from ambulatory care, 50% are in partial or full-time hospitalization care. Schizophrenia represents the first diagnosis that psychiatric sectors take in charge. Read More
Prog Neuropsychopharmacol Biol Psychiatry 2006 Aug 24;30(6):1163-6. Epub 2006 Apr 24.
Department of Psychiatry, International Hospital, Istanbul, Turkey.
Atypical antipsychotics commonly cause isolated asymptomatic increase in the aminotransferase levels. Among these atypical antipsychotics, mostly transient, asymptomatic increase in hepatic enzymes has been reported with olanzapine, however olanzapine rarely may induce a clinical and/or biological hepatic toxicity. The pathogenesis of olanzapine-associated hepatotoxicity is not well known and is mostly a transient phenomenon. Read More
Encephale 2007 Mar-Apr;33(2):188-96
CMPP du Gacet, ADPEP 35, 1 allée du Gacet, 35200 Rennes.
Introduction: A review of the literature from 1996-2004 on the indications and adverse reactions concerning the use of olanzapine, a second generation antipsychotic agent, in children and adolescents with psychiatric illness is made in this article. Studies lasted for 2 to 3 months and a few had a follow up period up to a year. Olanzapine, dosed from 2. Read More